You are here

Our science / Clinical Trials / Find a Trial / NCT00240214

Study Evaluating Rapamune in Patients After Kidney Transplantation

Back to Search Print Save as PDF Bookmark Trial

NCT00240214

Last updated on April 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Multiple Cities, , Germany
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Transplantation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients having received a renal allograft from a cadaveric or living donor with low
or moderate risk of developing acute rejection episodes.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Contraindications according to Summary of the Product Characteristics (SmPC).

NCT00240214
Pfizer
Terminated
Study Evaluating Rapamune in Patients After Kidney Transplantation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Renal Cell Carcinoma
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
NCT02776644
All Genders
Renal Cell Cancer
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
NCT02493751
All Genders
18+
Years
Multiple Sites
Renal Cell Carcinoma
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
NCT00460798
All Genders
Renal Transplantation
Study Evaluating Rapamune in Patients After Kidney Transplantation
NCT00240214
All Genders
0+
Years
Multiple Cities,
Study Evaluating Rapamune in Patients After Kidney Transplantation
An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime
The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
primary care clinic
Renal Transplantation
Drug: sirolimus
Tablet, dosage is determined by trough level
1
sirolimus
Intervention: Drug: sirolimus
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
500
February 2008
February 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes.

Exclusion Criteria:

  • Contraindications according to Summary of the Product Characteristics (SmPC).
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00240214
0468E-100875
Not Provided
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Germany, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
March 2008

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now